Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001558370-23-007274
Filing Date
2023-04-28
Accepted
2023-04-28 16:10:22
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tmb-20230428xdefa14a.htm DEFA14A 17376
2 GRAPHIC tmb-20230428xdefa14a_bg001.jpg GRAPHIC 168054
3 GRAPHIC tmb-20230428xdefa14a_bg002.jpg GRAPHIC 107067
  Complete submission text file 0001558370-23-007274.txt   397452
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40236 | Film No.: 23866148
SIC: 2834 Pharmaceutical Preparations